Live
Hindustan Unilever Ltd (HUL) is funding a research project to understand the immune response to SARS-CoV-2 among vaccinated people and vaccine efficacy among Indians.
The national-level research is being enabled by the office of the principal scientific adviser to the government of India’s programme that will work on collaborations between industry and academia.
HUL will also support additional analytical and data analyses through its R&D scientists to the consortium partners, it said.
- Transrail Lighting Bags Rs 459 Cr MENA Transmission Orders
- Kotak Mahindra Bank Hikes DCC Fee to 3.5% from August
- Jubilant Pharmova Arm Gets USFDA Nod for Antacid Drug
- TVS Motor Jumps 3.75% as NTORQ 125 Gets New Colours
- Fortis Healthcare Falls 2.25% as Delhi Govt Orders Probe
“This is a first-of-its-kind national-level multi-centre study on long-term protection and immunogenicity of vaccines, in combination with an understanding of nutritional and ‘skin immunity’ status in the Indian population,” the company said in a statement on Tuesday.
Stock Covered in the news
